

CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page number (Without Figures): 28 Rate: 6.2 CNY per page

Editing Fee: <u>173.6 CNY</u>

Figure count: <u>1</u> Figure handling time: 50 min Rate: <u>1 CNY per min</u>

Editing Fee: 50 CNY

XML and PDF converting time: 60 min Rate: 1 CNY per min

Editing Fee: <u>60</u> CNY

Manuscript word count: 5559

Total Editing Fee: 283.6 CNY

Scientific Editor: Li-Li Wang

Date of signature: <u>4/8/2022</u> (month/day/year)

		Comments
Item No.	Specific items for verification	Yes=[Y]
		No= [N]
	General Information of the Manuscript	
	Name of journal: World Journal of Gastrointestinal Surgery	
	Manuscript NO.: 71691	
	Column: Retrospective Study	
1	Title: Prognostic factors for patients with mass-forming intrahepatic	D.(
L	cholangiocarcinoma: A case series of 68 patients	[Y]
	Authors: Jian Feng, Bin Liang, Hang-yu Zhang, Zhe Liu, Kai Jiang	
	and Xiang-qian Zhao	
	Reviewer code: 06143370, 06143346, and 06143368	
	First decision: 2021-11-17 08:03	
2	Editorial Office's Comments	[Y]



	Science Editor: Remind Revision at 2021-11-25 08:18	
	Company Editor-in-Chief: I recommend the manuscript to be	
	published in the World Journal of Gastrointestinal Surgery.	
3	The fixed headings are copied.	[Y]
	The title concisely summarizes the main topic of the study and is	
	not too long (no more than 18 words). Words such as 'exploration',	
4	'research', 'analysis', 'observation', and 'investigation' are avoided.	[Y]
	The title does not start with 'The' and does not include any Arabic	
	numbers or uncommon abbreviations.	
5	A short running title is provided (no more than 6 words).	[Y]
	The authors' full family (sur)names and full/abbreviated first	
6	names are listed on the title page and are consistent with those	[Y]
	listed in the signed BPG Copyright License Agreement form.	
	The 'Author contributions' passage describes the specific	
	contribution(s) made by each author. The author's names are listed	
	in the following format: full family (sur)name followed by	
	abbreviated first and middles names.	
	<i>e.g.,</i> "Wang CL and Liang L contributed equally to this work; Wang	
7	CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the	[Y]
	research study; Wang CL, Zou CC, Hong F and Wu XM performed	
	the research; Xue JZ and Lu JR contributed new reagents and	
	analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and	
	Wang CL, Liang L and Fu JF wrote the manuscript. All authors	
	have read and approve the final manuscript."	
	The 'Supported by' statement describes the source(s) of financial	
8	support and includes the corresponding identification number(s)	[N]
	and program ID(s) if available, and contains no spelling errors.	



9The 'Corresponding author' passage provides the corresponding author's full first and family (sur)names, abbreviated title (e.g., MD, PhD), affiliated institute's name and complete postal address (including zip code) and e-mail (written in all lowercase), and contains no spelling errors.[M]10The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors.[M]11The Abstract section is formatted according to the article-specific style (structured cs unstructured) and word count thresholds, as follows: Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor; Non-structured abstract that is no less than 150 words. Research articles; Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[M]12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[M]13The ''citation'' contains authors' names and manuscript title. The name of the first author should be typed with the first letter capitalized, followed by their abbreviated first and middle initials. For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick[M]	r		
9 PhD), affiliated institute's name and complete postal address (including zip code) and e-mail (written in all lowercase), and contains no spelling errors. [M] 10 The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors. [M] 10 The Abstract section is formatted according to the article-specific style (structured <i>vs</i> unstructured) and word count thresholds, as follows: [M] 11 Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. [M] 11 Research articles; Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words). [M] 12 The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon. [M] 13 The "citation" contains authors' names and manuscript title. The name of the first author should be typed with the first letter capitalized, followed by their abbreviated first and middle initials. [M]		The 'Corresponding author' passage provides the corresponding	
10 (including zip code) and e-mail (written in all lowercase), and contains no spelling errors. 10 The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors. [Y] 10 The Abstract section is formatted according to the article-specific style (structured vs unstructured) and word count thresholds, as follows: [Y] 11 Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. [Y] 11 Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. [Y] 12 The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon. [Y] 13 The "citation" contains authors' names and manuscript title. The name of the first author should be typed with the first letter capitalized, followed by their abbreviated first and middle initials. [Y]	9	author's full first and family (sur)names, abbreviated title (e.g., MD,	
contains no spelling errors.Interview10The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors.[M]11The Abstract section is formatted according to the article-specific style (structured <i>vs</i> unstructured) and word count thresholds, as follows: Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. Research articles; Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[M]12The Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[M]13The "citation" contains authors' names and manuscript tille. The name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[M]		PhD), affiliated institute's name and complete postal address	[Y]
10 The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors. [Y] 11 The Abstract section is formatted according to the article-specific style (structured vs unstructured) and word count thresholds, as follows: [Y] 11 Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. [Y] 11 Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. [Y] 12 The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon. [Y] 13 The ''Citation'' contains authors' names and manuscript title. The name of the first author should be typed with the first letter capitalized, followed by their abbreviated first and middle initials. [Y]		(including zip code) and e-mail (written in all lowercase), and	
10started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors.[Y]11The Abstract section is formatted according to the article-specific style (structured vs unstructured) and word count thresholds, as follows: Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. Research articles; Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[Y]12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13[Sur Curation" contains authors' names and manuscript title. The name of the first author should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		contains no spelling errors.	
10Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors.[Y]The Abstract section is formatted according to the article-specific style (structured vs unstructured) and word count thresholds, as follows: Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor; Non-structured abstract that is no less than 150 words. Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[Y]12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		The Manuscript Tracking information (i.e., Received, Peer review	
Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors. Image: construct of the section is formatted according to the article-specific style (structured vs unstructured) and word count thresholds, as follows: Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words). 12 The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon. [M] 13 The "citation" contains authors' names and manuscript title. The capitalized, followed by their abbreviated first and middle initials. [M]	10	started, First decision, Revised, Accepted, Article in press, and	[2/]
11The Abstract section is formatted according to the article-specific style (structured vs unstructured) and word count thresholds, as follows: Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[Y]12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]	10	Published online) are provided along with the corresponding editor	[Y]
11style (structured vs unstructured) and word count thresholds, as follows: Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor; Non-structured abstract that is no less than 150 words. Research articles; Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[Y]12The 'Key words' list provides 5-10 keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of the first author should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		and date for each item, and contain no spelling errors.	
follows:Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor; Non-structured abstract that is no less than 150 words. Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[Y]12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		The Abstract section is formatted according to the article-specific	
11Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[Y]12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		style (structured vs unstructured) and word count thresholds, as	
11Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[Y]12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		follows:	
11Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[Y]12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		Commentary, Frontier, Diagnostic Advances, Medical Ethics,	
11Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).[Y]12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		Minireview, Review, Therapeutics Advances, and Topic Highlight:	
Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of the first author should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]	11	Non-structured abstract that is no less than 200 words.	[N/]
Research articles:Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]	11	Field of Vision, Case Report and Letter to the Editor:	[Y]
more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		Non-structured abstract that is no less than 150 words.	
(no less than 120 words); and CONCLUSION (no more than 26 words).12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		Research articles: Structured abstract with subsections for AIM (no	
words).The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		more than 20 words); METHODS (no less than 80 words); RESULTS	
12The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]13The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		(no less than 120 words); and CONCLUSION (no more than 26	
12content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.[Y]The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]		words).	
and each keyword is separated by a semicolon.The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.		The 'Key words' list provides 5-10 keywords that reflect the main	
13The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials.[Y]	12	content of the study. The first letter of each keyword is capitalized,	[Y]
 name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials. 		and each keyword is separated by a semicolon.	
13 (sur) name of all authors should be typed with the first letter [Y] capitalized, followed by their abbreviated first and middle initials.	13	The "citation" contains authors' names and manuscript title. The	
13 [Y] capitalized, followed by their abbreviated first and middle initials.		name of the first author should be typed in bold letters; the family	[Y]
capitalized, followed by their abbreviated first and middle initials.		(sur) name of all authors should be typed with the first letter	
For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick		capitalized, followed by their abbreviated first and middle initials.	
		For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick	
Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM,		Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM,	



	Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes	
	mellitus increases the risk of gastric cancer: A meta-analysis. World J	
	Gastroenterol 2019; In press	
	The 'Core tip' provides a summary (less than 100 words) of the	
14	study that outlines the most innovative and important arguments	[]]
14	and core contents of the paper and will serve to effectively attract	[Y]
	readers.	
	The 'INTRODUCTION' section clearly describes the relevant	
	background information for the study. Only the most relevant and	
	current (within the past 5 years) literature is cited, with the	
	exception of rare instances of seminal literature citations. All	
	technical terms and/or abbreviations are explained and/or defined,	
	with the full name of abbreviations given upon first appearance in	
15	the text and the abbreviation presented in parentheses [<i>i.e.</i> ,	[Y]
	"computed tomography (CT)"]. First-person pronouns (e.g., 'I',	
	'we') are used appropriately to clearly indicate the work performed	
	by the author(s). When weaknesses of previous studies are	
	described in the text to highlight the innovations related to the	
	current study, the information is presented carefully.	
	The 'MATERIALS AND METHODS' section clearly and accurately	
	describes all materials and methods used to obtain the data	
16	presented in the article and is adequate for a reader to repeat the	[Y]
	study.	
	The 'RESULTS' section concisely describes the observational and	
	experimental results. Representative data and data that have	
17	scientific significance are emphasized. Data is presented in either the text a table or figure (<i>i.e.</i> chart diagram graph or image) but is	[V]
1/	the text, a table or figure (<i>i.e.</i> , chart, diagram, graph or image), but is	[Y]
	not repeated among each. Information presented in the tables and	
	figures clearly describes the trends, meaning, and inferences.	
	Results described in textual form are accurate, concise and clear.	



	Statistical symbols are accurate. Statistical significance is expressed	
18	as ${}^{a}P < 0.05$, ${}^{b}P < 0.01$ ($P > 0.05$ usually does not need to be denoted).	
	If there are other series of <i>P</i> values, $^{c}P < 0.05$ and $^{d}P < 0.01$ are used,	[Y]
	and a third series of <i>P</i> values is expressed as $^{e}P < 0.05$ and $^{f}P < 0.01$.	
	Statistical data is expressed as mean \pm SD or mean \pm SE.	
	The 'DISCUSSION' section (1) describes the main purpose and	
	hypothesis of the study; (2) summarizes the most important results;	
	(3) illustrates and explains the results (but does not simply repeat	
10	the data) and draws conclusions or inferences based on the results;	D.a.
19	(4) points out the limitations of the study and their impact on the	[Y]
	results, as well as proposes further advice on future research	
	topic(s) or direction(s); and (5) describes the theoretical significance	
	and practical value of the findings.	
	The 'ACKNOWLEDGEMENTS' section expresses gratitude to any	
	individuals or organizations for technical support (i.e., providing	
20	instrumentation, equipment or experimental materials, and/or	[N]
20	assistance in experimental work), non-technical services (i.e., useful	
	inspiration, suggestions, guidance, or review), and/or any other	
	auxiliary work.	
01	The 'ARTICLE HIGHLIGHTS' section provides comments for	[2/]
21	original articles in accordance with the specified format.	[Y]
	The 'REFERENCES' section lists the references in the Vancouver	
	style. This style uses Arabic numeral in-text citations based on the	
	order of the first appearance of a source in the text. For citations	
22	where the author's name is indicated in the text, a superscript	[Y]
	number should be placed following the name (<i>i.e.,</i> "Pang <i>et al</i> "). For	
	citations where no author is indicated, a superscript number should	
	be placed at the end of the sentence. Respective examples are: "Ma ^[1]	
	reported", "Pan et al ^[2-5] indicated"; "PCR has a high	
	sensitivity ^[6,9] ." No superscript numbers are used when the	
L		



	reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> ^[2-5] , please see reference [8]).	
23	Journal references have been verified to ensure that there are no duplicate references and that the PMID numbers are correct. For references not yet included in PubMed: the name of Chinese journals is spelled out using Chinese Pinyin, with the first letter of each word capitalized (<i>e.g.</i> , <i>Shijie Huaren Xiaohua Zazhi</i>); the name of journals in other languages are listed according to indexing information retrieved from Google. Book references are presented with all the information relevant to the electronic version.	[Y]
24	The number of cited references is appropriate for the article type, as follows: <u>Commentary:</u> no less than 50; <u>Review:</u> no less than 100; <u>Article:</u> no less than 30/26; <u>Case Report and Letter to the Editor:</u> no less than 1.	[Y]
25	The ethics-related statements are provided in accordance with the manuscript type (<i>e.g.</i> , Manuscript NoInstitutional review board statement, Manuscript NoAnimal care and use statement, <i>etc.</i>).	[Y]
26	The names of the peer reviewers and the scientific editor are present at the end of the paper (<i>e.g.</i> , P-Reviewer: Hugot D S-Editor: Wang JL).	[Y]



27The order and numerical labeling of tables and figures is consistent with their appearance and presentation in the text. Symbols in tables (e.g., +, -, ×, +, +) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F:[M]28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[M]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[M]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[M]31The revised manuscript is provided (file name: Manuscript NoAnswering reviewers); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers).[M]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoClinical trial registration statement); (5) Instituti			
27tables (e.g., +, -, ×, +, *) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:[M]28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[M]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[M]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).[M]31The revised manuscript is provided (file name: Manuscript NoAnswering reviewers); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers).[M]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval		The order and numerical labeling of tables and figures is consistent	
27 footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; D:; E:; F: M 28 Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. M 29 The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript. M 30 The revised manuscript is provided (file name: Manuscript NoReview; <i>e.g.</i> , 870-Review). M 31 The letter of peer-reviewers' comments is provided (file name: Manuscript NoAnswering reviewers), <i>e.g.</i> , 870-Answering reviewers). M 32 The response letter is provided (file name: Manuscript NoAnswering reviewers), and approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		with their appearance and presentation in the text. Symbols in	
27consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F:[M]28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[M]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[M]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[M]31The revised manuscript is provided (file name: Manuscript NoReview), e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Answering reviewers).[M]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form[Y]		tables (e.g., +, -, \times , \div , *) correctly correspond to the definitions in the	
consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis idiagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	27	footnotes. Only one legend is provided for each multi-panel figure	[¥]
Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	21	consisting of color graphs, black and white graphs, or line graphs	[1]
treatment. A:; B:; C:; D:; E:; F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		that depicts data of the same theme. For example: Figure 1	
28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[M]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[M]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[M]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[M]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[M]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		Pathological changes in atrophic gastritis tissue before and after	
28graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement; (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		treatment. A:; B:; C:; D:; E:; F:	
28graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[M]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[M]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		Split pictures include flow charts, line graphs, histograms, and	
29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[M]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[M]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[M]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	28	graphs including text. Unsplit pictures include meta-analysis	[Y]
29InterferenceMaccording to the peer-reviewers' comments.M30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.M31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).M31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		diagrams, PCR amplification curves, and survival curves.	
according to the peer-reviewers' comments.Image: Comments and consistent with the responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[M]30The revised manuscript is provided (file name: Manuscript NoReview; <i>e.g.</i> , 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoReview; <i>e.g.</i> , 870- Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; <i>e.g.</i> , 870-Answering reviewers).[M]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript MoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	20	The author(s) highlighted the changes made to the manuscript	D.d
30[M]the changes made to the manuscript.[M]The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[M]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[M]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	29	according to the peer-reviewers' comments.	[Y]
the changes made to the manuscript.The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	20	The responses to the peer-reviewers' comments are consistent with	D.d
 NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form 	30	the changes made to the manuscript.	[Y]
31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form[Y]		The revised manuscript is provided (file name: Manuscript	
31[Y]Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		NoReview; <i>e.g.</i> , 870- Review).	
Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	21	The letter of peer-reviewers' comments is provided (file name:	[1/]
NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript32NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	51	Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).	[1]
The related ethics and relevant documents are provided, such as (1)Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		The response letter is provided (file name: Manuscript	
Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		NoAnswering reviewers; <i>e.g.</i> , 870-Answering reviewers).	
 approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form 		The related ethics and relevant documents are provided, such as (1)	
 form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file [Y] name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form 	32	Approved grant application form(s) or funding agency copy of any	
32 NoBiostatistics statement); (3) Conflict-of-interest statement (file [Y] name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		approval document(s) (file name: Manuscript NoGrant application	
name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		form(s)); (2) Biostatistics review certificate (file name: Manuscript	
trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		NoBiostatistics statement); (3) Conflict-of-interest statement (file	[Y]
registration statement); (5) Institutional review board approval form		name: Manuscript NoConflict-of-interest statement); (4) Clinical	
		trial registration statement (file name: Manuscript NoClinical trial	
or document (file name: Manuscript NoInstitutional review board		registration statement); (5) Institutional review board approval form	
		or document (file name: Manuscript NoInstitutional review board	



	statement); (6) Institutional animal care and use committee	
	approval form or document (file name: Manuscript	
	NoInstitutional animal care and use committee statement), and (7)	
	Signed informed consent form(s) or document(s) (file name:	
	Manuscript NoInformed consent statement).	
	All authors signed the BPG Copyright license agreement form (file	
33	name: Manuscript NoCopyright license agreement; e.g.,	[Y]
	870-Copyright license agreement).	
	The language certificate provided by authors who are non-native	
34	speakers of English meets the BPG requirements (file name:	[Y]
	Manuscript NoLanguage certificate; e.g., 870-Language certificate).	
	The photos licensed in the Agreement for Use of Personal Photos	
25	are consistent with those in the paper (file name: Manuscript	[N 1]
35	NoAgreement for use of personal photos; e.g., 870-Agreement for	[N]
	use of personal photos).	
	This document (Checklist of Responsibilities for Scientific Editors)	
36	has been saved under the file name: manuscript NoScientific	[Y]
	editor work list (e.g., 870-Scientific editor work list).	
	A CrossCheck investigation (an effective tool for detecting unoriginal	
	content, enabling our editors to preserve the journal's integrity and	
	the authors' copyright) has been performed for the manuscript via	
	the website: http://www.ithenticate.com/. The results document	
	contains the following information for the manuscript: "Name of	
37	journal", "Manuscript No.", "Columns", "Title" and "Author list".	[Y]
	The Figure of the CrossCheck results is saved in JPEG format (.jpg) at	
	1440 × 680 pixel resolution. The PDF of the CrossCheck results has	
	been saved under the file name: manuscript No CrossCheck report	
	(e.g., 870-CrossCheck report). The Google searches have also been	
	performed to further ensure publication of original content.	
38	The text of the manuscript is typed in Book Antiqua font, 12 pt, with	[Y]



	1.5 line spacing.	
Responsibilities of scientific editors	The primary responsibilities of our scientific editors include carefully entire manuscript and all accompanying materials for: (1) error grammar, punctuation and wording; (2) suitability of tables, figures, f legends; (3) accurate and appropriate presentation of symbols (<i>e.g.</i> +, tables and figures; and (4) complete and comprehensive revision of t	rs in spelling, igure data and -, ×, ÷, %, *) in
Publication process	according to the reviewers' comments.Manuscript reception and registration→Initial review by scientific editor→Peerreview→End of peer review→First round of meeting evaluation→To beaccepted→Revision by the author(s)→Second round of meeting evaluation→To beaccepted/revised/rejected→Final review by the Editor-in-Chief (final qualitycontrol for academic content and language quality)→Final acceptance and chargingof publication fee→Language editing→Production→Proofreading by scientificeditor→Proofreading by deputy editor→Final review by Editor-in-Chief→Releaseof online open-access papers in electronic form on the BPG website→Release ofonline papers on PubMed Central→Delivery of high-quality PDF reprints to theauthor(s)→End of the publication process.	